Mealey's (December 7, 2022, 5:21 PM EST) -- PHILADELPHIA — A federal judge in Pennsylvania granted final approval of a $1.4 million settlement in a securities class action lawsuit against a specialty pharmaceutical company and three of its senior executives on allegations that the defendants misrepresented the efficacy and manufacturing quality control for the development of the company’s non-opioid therapeutic drug candidate, but the judge awarded costs and fees lower than the amounts sought....